RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Abcellera Biologics Stock

Abcellera Biologics Net Income 2024

Abcellera Biologics Net Income

-181.63 M USD

Ticker

ABCL

ISIN

CA00288U1066

WKN

A2QKXS

In 2024, Abcellera Biologics's profit amounted to -181.63 M USD, a 24.06% increase from the -146.4 M USD profit recorded in the previous year.

The Abcellera Biologics Net Income history

YEARNET INCOME (undefined USD)
2030e-183.34
2029e114.21
2028e6.01
2027e-66.12
2026e-194.61
2025e-221.21
2024e-181.63
2023-146.4
2022158.5
2021153.5
2020118.9
2019-2.2
20180.3

Abcellera Biologics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Abcellera Biologics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Abcellera Biologics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Abcellera Biologics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Abcellera Biologics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Abcellera Biologics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Abcellera Biologics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Abcellera Biologics’s growth potential.

Abcellera Biologics Revenue, EBIT and net profit per share

DateAbcellera Biologics RevenueAbcellera Biologics EBITAbcellera Biologics Net Income
2030e199.54 M undefined-273.37 M undefined-183.34 M undefined
2029e115.44 M undefined-289.46 M undefined114.21 M undefined
2028e91.73 M undefined-300.54 M undefined6.01 M undefined
2027e121.67 M undefined-296.55 M undefined-66.12 M undefined
2026e86.56 M undefined-224.88 M undefined-194.61 M undefined
2025e49.59 M undefined-230.86 M undefined-221.21 M undefined
2024e34.27 M undefined-229.71 M undefined-181.63 M undefined
202338.03 M undefined-237.21 M undefined-146.4 M undefined
2022485.4 M undefined216.5 M undefined158.5 M undefined
2021375.2 M undefined204.4 M undefined153.5 M undefined
2020233.2 M undefined156 M undefined118.9 M undefined
201911.6 M undefined-4.1 M undefined-2.2 M undefined
20188.8 M undefined-800,000 undefined300,000 undefined

Abcellera Biologics stock margins

The Abcellera Biologics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Abcellera Biologics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Abcellera Biologics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Abcellera Biologics's sales revenue. A higher gross margin percentage indicates that the Abcellera Biologics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Abcellera Biologics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Abcellera Biologics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Abcellera Biologics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Abcellera Biologics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Abcellera Biologics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Abcellera Biologics Margin History

Abcellera Biologics Gross marginAbcellera Biologics Profit marginAbcellera Biologics EBIT marginAbcellera Biologics Profit margin
2030e0 %-137 %-91.88 %
2029e0 %-250.75 %98.94 %
2028e0 %-327.62 %6.55 %
2027e0 %-243.73 %-54.35 %
2026e0 %-259.81 %-224.84 %
2025e0 %-465.57 %-446.12 %
2024e0 %-670.34 %-530.02 %
20230 %-623.82 %-385 %
20220 %44.6 %32.65 %
20210 %54.48 %40.91 %
20200 %66.9 %50.99 %
20190 %-35.34 %-18.97 %
20180 %-9.09 %3.41 %

Abcellera Biologics Aktienanalyse

What does Abcellera Biologics do?

Abcellera Biologics Inc. is a leading biotechnology company specializing in the discovery of antibodies and the identification of therapies for serious diseases. The company was founded in Vancouver, Canada in 2012 and has since become a major player in the biotechnology field. It has formed numerous significant partnerships with large pharmaceutical companies in recent years and works closely with leading universities and research institutions worldwide. Abcellera Biologics Inc. follows a new, innovative business model that focuses on the discovery of antibodies through the application of cutting-edge technologies, data science, and machine learning. The company has developed a revolutionary technology platform called "Microfluidic Drop-based Technology" that is capable of discovering thousands of antibodies within just a few weeks. This technology allows for the rapid and efficient discovery of antibodies that can be used in the treatment of serious diseases. Abcellera Biologics Inc. is divided into several divisions that focus on antibody discovery, therapy development, collaborations with pharmaceutical companies, and services. Antibody discovery is carried out through years of research and development using state-of-the-art technologies and methods. Therapy development includes preclinical and clinical development of therapeutic products and conducting clinical trials. Abcellera Biologics Inc. works closely with leading pharmaceutical companies in the industry to develop new therapies and discover antibodies. The company has already formed numerous partnerships with major pharmaceutical companies such as Pfizer, Sanofi, GlaxoSmithKline, AbbVie, and Biogen. Another important focus of Abcellera Biologics Inc. is providing services in the field of antibody development. The company has extensive expertise in antibody discovery and therefore offers services to other companies. This allows other companies to benefit from Abcellera Biologics Inc.'s unique technology platform and top-notch capabilities. Abcellera Biologics Inc.'s product portfolio includes various antibody therapies targeting the treatment of specific diseases. One of the company's most promising products is the "LY-CoV555" antibody therapy used for COVID-19. This therapy was developed in collaboration with Eli Lilly and is currently being tested in clinical trials. Overall, Abcellera Biologics Inc. has become a leading company in the biotechnology industry. Its focus on antibody discovery through state-of-the-art technologies and data-driven methods, as well as successful collaborations with major pharmaceutical companies, makes it an important player in the industry. Abcellera Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Abcellera Biologics's Profit Margins

The profit margins of Abcellera Biologics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Abcellera Biologics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Abcellera Biologics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Abcellera Biologics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Abcellera Biologics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Abcellera Biologics stock

How much profit has Abcellera Biologics made this year?

Abcellera Biologics has made -181.63 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 24.06% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Abcellera Biologics publish its earnings?

Abcellera Biologics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Abcellera Biologics?

The profits of Abcellera Biologics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Abcellera Biologics?

You can learn more about the earnings of Abcellera Biologics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Abcellera Biologics pay?

Over the past 12 months, Abcellera Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Abcellera Biologics is expected to pay a dividend of 0 USD.

What is the dividend yield of Abcellera Biologics?

The current dividend yield of Abcellera Biologics is .

When does Abcellera Biologics pay dividends?

Abcellera Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Abcellera Biologics?

Abcellera Biologics paid dividends every year for the past 0 years.

What is the dividend of Abcellera Biologics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Abcellera Biologics located?

Abcellera Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Abcellera Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Abcellera Biologics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Abcellera Biologics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Abcellera Biologics in the year 2023?

In the year 2023, Abcellera Biologics distributed 0 USD as dividends.

In which currency does Abcellera Biologics pay out the dividend?

The dividends of Abcellera Biologics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Abcellera Biologics

Our stock analysis for Abcellera Biologics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Abcellera Biologics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.